Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Malignant Neoplasm of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04267120 | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally… | Phase 2 | terminated | Feb 12, 2020 | Washington University School of Medicine | Slow enrollment with low accrual | Enrollment / accrual |
| NCT06884683 | Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma(NivoMet) | Phase 2 | terminated | Mar 19, 2025 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | slow enrollment | Enrollment / accrual |
| NCT00448240 | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced… | Phase 2 / Phase 3 | terminated | Mar 16, 2007 | Henry Ford Health System | Low Accrual, Funding | Enrollment / accrual |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Phase 1 / Phase 2 | terminated | Sep 24, 2019 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
| NCT05452408 | Antitumor-B KAC PK Study | Phase 1 | withdrawn | Jul 11, 2022 | Medical College of Wisconsin | Study abandoned. | Other (stated, no rule matched) |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | N/A | withdrawn | Nov 22, 2023 | Montefiore Medical Center | PI indicated that the site was unable to procure shunt. No participants were enrolled and this… | Enrollment / accrual |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Early Phase 1 | terminated | Jul 11, 2016 | Wake Forest University Health Sciences | Study closed prior to meeting enrollment goal and funding issues | Enrollment / accrual |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT03115476 | A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin… | Phase 3 | terminated | Apr 14, 2017 | LEO Pharma | Study halted prematurely and will not resume; participants are no longer being examined. | Other (stated, no rule matched) |
| NCT05137899 | Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy(ADVANCE HCC) | Phase 2 | terminated | Nov 30, 2021 | Ontario Clinical Oncology Group (OCOG) | Recruitment challenges, Hoffman La Roche strategic priority shift | Enrollment / accrual |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With… | Phase 2 | withdrawn | Feb 24, 2023 | Replimune, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | terminated | Mar 16, 2023 | Great Novel Therapeutics Biotech & Medicals Corporation | The overall profile does not support development for Hepatocellular Carcinoma | Other (stated, no rule matched) |
| NCT03387592 | CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas(SENECA) | Phase 2 | terminated | Jan 2, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Efficacy endpoint not met according to first step of Briant-Day design | Efficacy / futility |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03812289 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | N/A | terminated | Jan 23, 2019 | OHSU Knight Cancer Institute | PI decision | Other (stated, no rule matched) |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer… | Phase 2 | terminated | Aug 3, 2020 | Emory University | This study was terminated after interim analyses showed no benefits. | Efficacy / futility |
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | Phase 1 / Phase 2 | terminated | Feb 27, 2025 | Zhejiang Raygene Pharmaceuticals Co., Ltd | Company Operational Strategy Adjustment | Sponsor / business decision |
| NCT04268888 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC(TACE-3) | Phase 2 / Phase 3 | suspended | Feb 13, 2020 | The Clatterbridge Cancer Centre NHS Foundation Trust | Analysis meant the study should close to recruitment | Enrollment / accrual |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy… | Phase 1 | terminated | May 29, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced… | Phase 3 | terminated | Jan 14, 2021 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | IDMC recommended to terminate the study since Interim analysis showed that the experimental group… | Efficacy / futility |
| NCT02464007 | Study of rSIFN-co for Patients With Advanced Solid Tumors | Phase 1 | terminated | Jun 8, 2015 | Sichuan Huiyang Life Science and Technology Corporation | Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov… | Other (stated, no rule matched) |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04465487 | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | Phase 1 | terminated | Jul 10, 2020 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell… | Phase 1 | terminated | Aug 6, 2020 | Shattuck Labs, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in… | Phase 1 / Phase 2 | withdrawn | May 25, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy… | Phase 1 / Phase 2 | withdrawn | Jun 5, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine(TNBC) | Phase 2 | withdrawn | Jun 12, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04804696 | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal… | Phase 2 | terminated | Mar 18, 2021 | Peking University | Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant… | Other (stated, no rule matched) |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Sep 26, 2023 | Alentis Therapeutics AG | Reprioritization of Trial | Other (stated, no rule matched) |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC…(PREPARE) | Phase 3 | terminated | Jan 9, 2017 | AIO-Studien-gGmbH | insufficient accrual rate | Enrollment / accrual |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing… | Phase 1 | terminated | Oct 19, 2020 | Hyunseok Kang, MD | Slow Accrual | Enrollment / accrual |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas…(PIOPPO) | Phase 2 | terminated | Jan 30, 2019 | CNAO National Center of Oncological Hadrontherapy | The study was early closed due to low accrual in August 2022. | Enrollment / accrual |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | Phase 2 | terminated | Sep 21, 2010 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04432532 | Neuroendocrine and Adrenal Tumors(NETAT) | — | withdrawn | Jun 16, 2020 | University of Pennsylvania | Change in research direction | Other (stated, no rule matched) |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Phase 1 | terminated | Apr 28, 2021 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Phase 1 | terminated | Feb 16, 2022 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | Phase 1 | withdrawn | Mar 25, 2022 | Ohio State University Comprehensive Cancer Center | PI Decision | Other (stated, no rule matched) |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver… | N/A | suspended | Oct 17, 2016 | St. Louis University | IRB reviewing study conduct and adverse events | Safety / toxicity |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes… | Phase 1 / Phase 2 | terminated | Dec 13, 2017 | Janssen Research & Development, LLC | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical… | Efficacy / futility |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and…(MYCHELANGELO I) | Phase 1 / Phase 2 | terminated | Aug 11, 2022 | Omega Therapeutics | Sponsor decision to terminate after monotherapy dose escalation. | Sponsor / business decision |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 21, 2025source: clinicaltrials